# Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

> **NCT01682811** · PHASE1 · COMPLETED · sponsor: **Harry T Whelan, MD** · enrollment: 20 (actual)

## Conditions studied

- Neurofibromatoses

## Interventions

- **DRUG:** Part 1 Levulan injection
- **DRUG:** Part 1 Levulan surface application
- **DRUG:** Part 1 Levulan surface application twice
- **DRUG:** Part 1 Levulan surface application twice with microneedling
- **DRUG:** Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1
- **DRUG:** Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2
- **DRUG:** Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3

## Key facts

- **NCT ID:** NCT01682811
- **Lead sponsor:** Harry T Whelan, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-12
- **Primary completion:** 2015-10-23
- **Final completion:** 2016-07-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01682811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01682811, "Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01682811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*